Danaher (DHR) Q4 2025 earnings review
Recovery Broadens as Life Sciences Turns a Corner
Danaher ended 2025 with a solid beat, delivering $2.23 Adjusted EPS (+4% YoY) and 2.5% core revenue growth. The narrative of a 'gradual recovery' is playing out: Biotechnology remains the steady engine (+6% core), but the critical development is Life Sciences flipping to positive growth (+0.5%) for the first time in FY25. Management's FY26 guidance ($8.35-$8.50 EPS) implies confidence in continued acceleration, forecasting 3-6% core revenue growth—a clear step up from the 2% achieved in FY25.
🐂 Bull Case
The Biotechnology segment (Bioprocessing) continues to outperform, growing core revenue by 6.0% in Q4. This segment has proven resilient despite broader market volatility, anchored by recurring consumables revenue.
Management expects >100bps of operating margin expansion in FY26. With the top line recovering (guided 3-6% growth), Danaher's high fixed-cost leverage and 'Danaher Business System' (DBS) efficiencies should drive outsized earnings growth.
🐻 Bear Case
While still positive, Diagnostics core growth slowed to 2.0% in Q4 from 3.5% in Q3. Given this is the largest revenue segment ($2.7B), any structural slowdown here dampens the overall recovery narrative.
Q1 2026 guidance calls for 'low-single digit' growth, while the full year guides to 3-6%. This implies a steep ramp-up in H2 2026, increasing execution risk if the macro environment worsens.
⚖️ Verdict: 🟢
Bullish. The return to growth in Life Sciences removes a major overhang. FY26 guidance is constructive, promising high-single-digit earnings growth driven by volume recovery and margin expansion. The portfolio is stabilizing nicely.
Key Themes
Biotechnology Remains the Anchor
Biotechnology (Bioprocessing) continues to carry the growth load, posting 6.0% core growth in Q4. This marks stability after a volatile post-COVID destocking period. Management cited 'continued strength in our bioprocessing business' as a primary driver for the quarter's beat.
Life Sciences Inflection
Reversing. For the first time in FY25, Life Sciences posted positive core growth (+0.5%), recovering from a -4.0% trough in Q1. While the growth is barely positive, it signals the end of the severe instrument destocking and funding headwinds that plagued the sector throughout 2024 and early 2025.
Currency and Tariff Headwinds
Currency exchange rates negatively impacted sales by 2.5% in Q4, masking the underlying strength of the business (4.5% GAAP growth vs 2.5% Core). Furthermore, forward-looking statements explicitly flag 'impact of tariffs' as a risk factor, which management previously quantified in Q1 2025 as a potential $350M gross exposure.
Innovation Pipeline Executing
Danaher is not resting on its installed base. Q4 saw the rollout of the Cytiva X-platform bioreactors (improving yields) and the Cepheid Xpert GI Panel (11 pathogens, 1 sample). These high-value launches are critical for maintaining pricing power in a lower-inflation environment.
Diagnostics Softness
Decelerating. Diagnostics core growth stepped down to +2.0% in Q4 from +3.5% in Q3. Given this segment faces headwinds from Volume-Based Procurement (VBP) in China (cited in previous quarters as a ~$100M drag), this deceleration warrants close monitoring in the Q1 2026 call.
Other KPIs
Beat. Came in above the high end of the implicit guidance. grew 4.0% YoY. For the full year, EPS hit $7.80, landing at the very top of the previously raised $7.70-$7.80 range.
Stable. Free Cash Flow conversion remains a highlight. Operating Cash Flow to Net Earnings conversion was 178% for the full year. This robust cash generation supports the dividend and potential M&A.
Stable. The company maintained a gross profit margin profile near 60% for the year, confirming that cost actions and the DBS system are effectively offsetting inflationary and tariff pressures.
Guidance
Accelerating. Compared to FY25's 2.0% core growth, this outlook signals a definitive shift to expansion. Management cites a 'gradual improvement in end markets' continuing into 2026.
Accelerating. Implies ~7-9% YoY growth from FY25's $7.80. This aligns with the 'high-single digit' growth ambition management teased in Q3.
Stable/Soft. The start of the year remains muted, similar to Q4 2025. This implies the acceleration to the 3-6% FY target is expected to materialize in Q2-Q4.
Key Questions
Diagnostics Deceleration Drivers
Diagnostics core growth slowed from 3.5% in Q3 to 2.0% in Q4. Was this solely due to the previously discussed China VBP headwinds, or are you seeing softening clinical demand in developed markets?
Life Sciences Recovery Shape
Life Sciences just turned positive (+0.5%). With FY26 guidance calling for 3-6% total growth, what assumptions are you making for the Life Sciences ramp? Is this reliant on a specific recovery in biopharma R&D spend?
Capital Deployment Priorities
With FCF conversion at ~178% and a clean balance sheet (~2.5x leverage), how are you balancing the M&A funnel against share buybacks, especially given the 'significant capital deployment capacity' mentioned in the presentation?
Tariff Mitigation Updates
Earlier in 2025, you estimated a ~$350M gross tariff impact. With the new administration's policies becoming clearer, has this exposure estimate changed for FY26, and how much is priced into the $8.35-$8.50 guide?